Monday, November 2, 2026
BTC $78,143 ▲ 0.04%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
BTC$78,143up+0.04%ETH$2,293up+0.95%SOL$94.51down−1.02%XRP$1.25up+0.03%LINK$11.31down−3.67%ADA$0.191down−0.94%S&P 5007,580down−1.82%Nasdaq25,437down−2.86%Dow51,770down−1.09%RUT2,812down−1.66%TNX4.93%down−1.20%TYX5.31%down−0.38%FVX4.72%down−1.67%IRX3.97%down−0.63%VIX19.01down−2.11%GOLD$3,910.60up+0.30%SILVER$50.39up+2.25%OIL$99.73down−4.22%DXY101.45down−0.42%NVDA$204.64down−4.22%AAPL$344.63down−1.23%TSLA$399.81down−0.87%META$614.99down−1.53%MSFT$521.91down−1.55%AMZN$240.35down−1.41%GOOGL$279.84down−1.40%Fear & Greed37 — FearBTC$78,143up+0.04%ETH$2,293up+0.95%SOL$94.51down−1.02%XRP$1.25up+0.03%LINK$11.31down−3.67%ADA$0.191down−0.94%S&P 5007,580down−1.82%Nasdaq25,437down−2.86%Dow51,770down−1.09%RUT2,812down−1.66%TNX4.93%down−1.20%TYX5.31%down−0.38%FVX4.72%down−1.67%IRX3.97%down−0.63%VIX19.01down−2.11%GOLD$3,910.60up+0.30%SILVER$50.39up+2.25%OIL$99.73down−4.22%DXY101.45down−0.42%NVDA$204.64down−4.22%AAPL$344.63down−1.23%TSLA$399.81down−0.87%META$614.99down−1.53%MSFT$521.91down−1.55%AMZN$240.35down−1.41%GOOGL$279.84down−1.40%Fear & Greed37 — Fear
Tag

syndax pharmaceuticals

1 article

Syndax's IPF Setback Forces Growth Bet on Niktimvo and Revuforj
U.S. Equities20d ago
Syndax's IPF Setback Forces Growth Bet on Niktimvo and Revuforj
Axatilimab failed to slow lung decline in Phase 2, forcing Syndax to abandon IPF expansion and lean on existing oncology and GVHD franchises to hit 2029 targets.